Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Dysfunctional uterine bleeding.

I T Cameron

    Bailliere'S Clinical Obstetrics and Gynaecology
    |June 1, 1989
    PubMed
    Summary
    This summary is machine-generated.

    Dysfunctional uterine bleeding (DUB) is diagnosed by excluding other causes of abnormal menses, often linked to endometrial factors. Medical treatments like NSAIDs or antifibrinolytics can reduce blood loss, with surgery as a last resort.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    The 'Developmental Origins' Hypothesis: relevance to the obstetrician and gynecologist.

    Journal of developmental origins of health and disease·2015
    Same author

    The levonorgestrel intrauterine system: the benefits of reduced bleeding.

    The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception·2014
    Same author

    Maternal muscle mass may influence system A activity in human placenta.

    Placenta·2010
    Same author

    Effect of asoprisnil on uterine proliferation markers and endometrial expression of the tumour suppressor gene, PTEN.

    Human reproduction (Oxford, England)·2009
    Same author

    The effects of the selective progesterone receptor modulator asoprisnil on the morphology of uterine tissues after 3 months treatment in patients with symptomatic uterine leiomyomata.

    Human reproduction (Oxford, England)·2007
    Same author

    L-serine uptake by human placental microvillous membrane vesicles.

    Placenta·2006
    Same journal

    The use of gonadotrophin-releasing hormone antagonists in polycystic ovarian disease.

    Bailliere's clinical obstetrics and gynaecology·2000
    Same journal

    Use of luteinizing hormone releasing hormone agonists in polycystic ovary syndrome.

    Bailliere's clinical obstetrics and gynaecology·2000
    Same journal

    Epithelial ovarian cancer, infertility and induction of ovulation: possible pathogenesis and updated concepts.

    Bailliere's clinical obstetrics and gynaecology·2000
    Same journal

    Complications of ovarian stimulation.

    Bailliere's clinical obstetrics and gynaecology·2000
    Same journal

    Adverse effects of luteinizing hormone on fertility: fact or fantasy.

    Bailliere's clinical obstetrics and gynaecology·2000
    Same journal

    Surgical management of polycystic ovarian syndrome.

    Bailliere's clinical obstetrics and gynaecology·2000
    See all related articles

    Area of Science:

    • Gynecology
    • Reproductive Endocrinology

    Background:

    • Dysfunctional uterine bleeding (DUB) accounts for 80% of menorrhagia cases.
    • Over 80% of DUB cases show no hypothalamo-pituitary-ovarian axis abnormalities, suggesting local endometrial factors.
    • Endometrial vasodilatory prostaglandins and increased fibrinolytic activity are implicated in DUB-related menorrhagia.

    Purpose of the Study:

    • To review the diagnosis and management of dysfunctional uterine bleeding.
    • To outline current medical and surgical treatment options for menorrhagia due to DUB.

    Main Methods:

    • Diagnosis involves excluding organic causes through history, examination, and investigations.
    • Medical treatments include NSAIDs, antifibrinolytics, ovarian suppressants, and hormonal therapies.
    • Surgical options include hysterectomy and endometrial ablation.

    Related Experiment Videos

    Main Results:

    • NSAIDs and antifibrinolytics reduce blood loss by 25-50%.
    • Ovarian suppressants are effective but have side effects or convenience issues.
    • Heavy menstrual bleeding may be subjective, with normal blood loss in up to 50% of reported menorrhagia cases.

    Conclusions:

    • DUB diagnosis relies on excluding organic pathology.
    • Medical management is the first-line approach for DUB.
    • Surgical intervention is considered when medical treatments fail, with less invasive options emerging.